Sanofi announced a mixed performance in Q2. While the operating results for the quarter were impressive and it upgraded the business EPS guidance, the Bioverative acquisition has shown to be a deal pursued in haste. An impairment charge of €1.8bn, mainly related to haemophilia drug, Eloctate, is being recorded. The specialty side (rare diseases, multiple sclerosis, etc.) and vaccines came in strongly, while consumer health remained mediocre and primary care (including diabetes, other mat
01 Aug 2019
Top-line beat but haemophilia reality bites
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Top-line beat but haemophilia reality bites
Sanofi announced a mixed performance in Q2. While the operating results for the quarter were impressive and it upgraded the business EPS guidance, the Bioverative acquisition has shown to be a deal pursued in haste. An impairment charge of €1.8bn, mainly related to haemophilia drug, Eloctate, is being recorded. The specialty side (rare diseases, multiple sclerosis, etc.) and vaccines came in strongly, while consumer health remained mediocre and primary care (including diabetes, other mat